Our History: A Marriage of Social and Commercial Objectives
The Bill & Melinda Gates Foundation and J.P. Morgan created the Global Health Investment Fund (GHIF) in 2012. These organizations sought to test the idea of building an impact investment portfolio from the most promising drug, vaccine, diagnostic, and medical device technologies that address high-burden public health challenges, neglected infectious diseases, and maternal/infant mortality. An emerging track record of success suggests it is possible to have one’s cake and eat it too, as GHIF technologies are being commercialized at scale and improving public health in historically overlooked markets. Over a relatively short period of time, the GHIF team has built a portfolio of 15 high-impact global health R&D programs that is on track to exceed the fund’s original financial return targets.
Adjuvant was incubated at GHIF and now stands as an independent investment platform designed to scale the most promising investment strategies developed within the original portfolio.